BEAT Tuberculosis is a phase 3, open label, multi-centre, randomized controlled trial. The purpose of this trial is to compare the efficacy and safety of a Study Strategy consisting of 6 months of bedaquiline (BDQ), delamanid (DLM), and linezolid (LNZ), with levofloxacin (LVX) and clofazimine (CFZ) compared to the current South African Standard of Care (Control Strategy) for 9 months for the treatment of rifampicin resistant (RR-TB) Tuberculosis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The proportion of participants with a successful outcome at the end of treatment
Timeframe: From 24 weeks to 76 weeks depending on assigned strategy and type of TB
The proportion of participants with a successful outcome at the end of follow up at 76 weeks post treatment initiation
Timeframe: At the end of follow up at 76 weeks post treatment initiation
The proportion of participants who experience grade 3 or greater adverse events during treatment and up to 30 days following the end of treatment
Timeframe: From treatment initiation to 30 days following the end of treatment